BRPI0512173A - composição imunogênica, e, métodos para potenciar uma resposta imune especìfica a um antìgeno, para estimular uma resposta celular com secreção de citocinas, para gerar uma resposta imune em um mamìfero em necessidade do mesmo contra oncocerciase, e para prevenir sars, e hiv em um mamìfero em necessidade do mesmo - Google Patents

composição imunogênica, e, métodos para potenciar uma resposta imune especìfica a um antìgeno, para estimular uma resposta celular com secreção de citocinas, para gerar uma resposta imune em um mamìfero em necessidade do mesmo contra oncocerciase, e para prevenir sars, e hiv em um mamìfero em necessidade do mesmo

Info

Publication number
BRPI0512173A
BRPI0512173A BRPI0512173-6A BRPI0512173A BRPI0512173A BR PI0512173 A BRPI0512173 A BR PI0512173A BR PI0512173 A BRPI0512173 A BR PI0512173A BR PI0512173 A BRPI0512173 A BR PI0512173A
Authority
BR
Brazil
Prior art keywords
mammal
need
antigen
immune response
response
Prior art date
Application number
BRPI0512173-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Angus J Macdonald
Sara Lustigman
Original Assignee
New York Blood Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Ct Inc filed Critical New York Blood Ct Inc
Publication of BRPI0512173A publication Critical patent/BRPI0512173A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/822—Protozoa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0512173-6A 2004-06-15 2005-06-15 composição imunogênica, e, métodos para potenciar uma resposta imune especìfica a um antìgeno, para estimular uma resposta celular com secreção de citocinas, para gerar uma resposta imune em um mamìfero em necessidade do mesmo contra oncocerciase, e para prevenir sars, e hiv em um mamìfero em necessidade do mesmo BRPI0512173A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58025404P 2004-06-15 2004-06-15
PCT/US2005/021004 WO2005122739A2 (en) 2004-06-15 2005-06-15 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus

Publications (1)

Publication Number Publication Date
BRPI0512173A true BRPI0512173A (pt) 2008-02-12

Family

ID=35510217

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512173-6A BRPI0512173A (pt) 2004-06-15 2005-06-15 composição imunogênica, e, métodos para potenciar uma resposta imune especìfica a um antìgeno, para estimular uma resposta celular com secreção de citocinas, para gerar uma resposta imune em um mamìfero em necessidade do mesmo contra oncocerciase, e para prevenir sars, e hiv em um mamìfero em necessidade do mesmo

Country Status (13)

Country Link
US (3) US7700120B2 (https=)
EP (1) EP1768696B1 (https=)
JP (1) JP4825797B2 (https=)
KR (1) KR20070048140A (https=)
CN (1) CN101151049A (https=)
AU (1) AU2005254087B2 (https=)
BR (1) BRPI0512173A (https=)
CA (1) CA2570218C (https=)
ES (1) ES2549669T3 (https=)
IL (1) IL180079A (https=)
NZ (1) NZ552583A (https=)
WO (1) WO2005122739A2 (https=)
ZA (1) ZA200700457B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4683740B2 (ja) * 2001-02-15 2011-05-18 明治乳業株式会社 炎症に伴う症状の軽減剤
NZ552583A (en) * 2004-06-15 2009-09-25 New York Blood Ct Inc Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
US9592287B2 (en) 2009-10-09 2017-03-14 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
CN103554241B (zh) * 2013-10-25 2015-04-15 中国人民解放军军事医学科学院微生物流行病研究所 一种具有免疫调节活性的重组蛋白asppr及应用
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
JP6256460B2 (ja) 2015-12-28 2018-01-10 日亜化学工業株式会社 チオガレート系蛍光体の製造方法
US20190142916A1 (en) 2016-04-01 2019-05-16 New York Blood Center, Inc. Biomarkers and immunogenic compositions for filarial parasites
JP6561976B2 (ja) 2016-12-02 2019-08-21 日亜化学工業株式会社 チオガレート系蛍光体の製造方法、発光装置の製造方法、チオガレート系蛍光体及び発光装置

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370265A (en) * 1974-10-22 1983-01-25 Agence Nationale De Valorisation Water soluble agents effective as immunological adjuvants for stimulating in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US5169840A (en) 1991-03-27 1992-12-08 Nobipols Forskningsstiftelse Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation
US20020102273A1 (en) * 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
US5789194A (en) * 1995-05-23 1998-08-04 Heska Corporation Parasitic helminth venom allergen antigen 5-like genes and proteins
US6682746B2 (en) 1995-09-21 2004-01-27 Kristina J. Hennessy Adjuvanted vaccine which is substantially free of non-host albumin
WO1998048832A1 (en) 1997-05-01 1998-11-05 Protechtion Unlimited, Inc. Nerve growth factor as a vaccine adjuvant
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
NZ508013A (en) 1998-05-07 2003-08-29 Corixa Corp Adjuvant composition for use with an antigen in a vaccine composition
FR2790959B1 (fr) * 1999-03-15 2003-06-27 Pf Medicament Utilisation de fractions membranaires bacteriennes a effet adjuvant, leurs procedes de preparation et composition pharmaceutique les contenant
ATE397942T1 (de) 1999-03-26 2008-07-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
US6537552B1 (en) 1999-10-19 2003-03-25 Iowa State University Research Foundation Vaccine adjuvant
US6723322B1 (en) * 2000-04-03 2004-04-20 New York Blood Center, Inc. Angiogenic Onchocerca volvulus proteins and uses thereof
JP2004529906A (ja) * 2001-03-19 2004-09-30 イオマイ コーポレイシヨン 経皮的免疫賦活
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
GB0123756D0 (en) * 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
NZ552583A (en) 2004-06-15 2009-09-25 New York Blood Ct Inc Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus

Also Published As

Publication number Publication date
US9017699B2 (en) 2015-04-28
IL180079A (en) 2013-12-31
EP1768696A4 (en) 2008-02-13
IL180079A0 (en) 2007-05-15
US9255140B2 (en) 2016-02-09
WO2005122739A3 (en) 2006-08-10
US20100266634A1 (en) 2010-10-21
CN101151049A (zh) 2008-03-26
AU2005254087B2 (en) 2010-12-09
CA2570218A1 (en) 2005-12-29
WO2005122739A2 (en) 2005-12-29
JP4825797B2 (ja) 2011-11-30
JP2008502695A (ja) 2008-01-31
CA2570218C (en) 2015-11-10
US20090191229A1 (en) 2009-07-30
ES2549669T3 (es) 2015-10-30
AU2005254087A1 (en) 2005-12-29
EP1768696B1 (en) 2015-08-12
US7700120B2 (en) 2010-04-20
US20060039921A1 (en) 2006-02-23
EP1768696A2 (en) 2007-04-04
NZ552583A (en) 2009-09-25
ZA200700457B (en) 2008-08-27
KR20070048140A (ko) 2007-05-08

Similar Documents

Publication Publication Date Title
DK1635863T3 (da) Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
WO2007067681A3 (en) Immunostimulatory compositions and methods
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
TR200102739T2 (tr) Aşı
BRPI0510430A (pt) composições e métodos para vacinação mucosal
EP2258712A3 (en) Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
TW200602077A (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
WO2008100598A3 (en) A method for enhancing t cell response
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
WO2009133378A3 (en) Products and methods for stimulating an immune response
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
DE602005026290D1 (de) Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
ZA202310611B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR122018075729B8 (pt) flavivírus na preparação de uma composição de vacina
CU23759A3 (es) Composiciones inmunogénicas
WO2006095330A3 (en) Methods and immunogenic cell preparations for treating antigen-associated diseases
BRPI0512173A (pt) composição imunogênica, e, métodos para potenciar uma resposta imune especìfica a um antìgeno, para estimular uma resposta celular com secreção de citocinas, para gerar uma resposta imune em um mamìfero em necessidade do mesmo contra oncocerciase, e para prevenir sars, e hiv em um mamìfero em necessidade do mesmo
DK1259259T3 (da) Mucosal adjuvansformulering
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
EP1594533A4 (en) Antibody vaccine conjugates and uses therefor
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
BRPI0514884A (pt) composição vacinal para gerar resposta imune celular e humoral protetora contra a infecção pelo vìrus de hepatite c
EA200700017A1 (ru) Способ усиления иммунного ответа на вакцину

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.